BR9908424A - Processo para purificar uma preparação de herpesvìrus - Google Patents
Processo para purificar uma preparação de herpesvìrusInfo
- Publication number
- BR9908424A BR9908424A BR9908424-4A BR9908424A BR9908424A BR 9908424 A BR9908424 A BR 9908424A BR 9908424 A BR9908424 A BR 9908424A BR 9908424 A BR9908424 A BR 9908424A
- Authority
- BR
- Brazil
- Prior art keywords
- groups
- herpesviruses
- purify
- preparation
- polysacharide
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 241001529453 unidentified herpesvirus Species 0.000 title abstract 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 229960000633 dextran sulfate Drugs 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012266 salt solution Substances 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"PROCESSO PARA PURIFICAR UMA PREPARAçãO DE HERPESVìRUS" Preparações de herpesvírus, por exemplo, do tipo HSV 2 cultivado, por exemplo, vírus geneticamente incapacitado para o uso em vacina, pode ser purificado, por exemplo, para a subsequente formulação farmacêutica com reagentes de afinidade de fase sólida contendo grupos de ligação que compreendem sulfato ou sulfonato, por exemplo, grupos de polissacarídeo sulfatados, por exemplo, sulfato de heparina ou de dextrano e eluindo-se, por exemplo, com soluções salinas. O processo pode ser combinado com outras etapas de cultura e de coleta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9804632.9A GB9804632D0 (en) | 1998-03-05 | 1998-03-05 | Virus preparations and methods |
| PCT/GB1999/000669 WO1999045104A2 (en) | 1998-03-05 | 1999-03-05 | Purification of virus preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9908424A true BR9908424A (pt) | 2000-10-31 |
Family
ID=10827994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9908424-4A BR9908424A (pt) | 1998-03-05 | 1999-03-05 | Processo para purificar uma preparação de herpesvìrus |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6267967B1 (pt) |
| EP (1) | EP1062325B1 (pt) |
| JP (1) | JP2002505101A (pt) |
| AT (1) | ATE316571T1 (pt) |
| AU (1) | AU3266599A (pt) |
| BR (1) | BR9908424A (pt) |
| CA (1) | CA2322615A1 (pt) |
| DE (1) | DE69929612T2 (pt) |
| DK (1) | DK1062325T3 (pt) |
| ES (1) | ES2257867T3 (pt) |
| GB (1) | GB9804632D0 (pt) |
| PT (1) | PT1062325E (pt) |
| WO (1) | WO1999045104A2 (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| WO2003023026A1 (en) * | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| CA2482512C (en) | 2002-04-30 | 2011-09-20 | Oncolytics Biotech Inc. | Improved viral purification methods |
| US20040208848A1 (en) | 2002-12-13 | 2004-10-21 | Smith Jonathan F. | Multi-antigenic alphavirus replicon particles and methods |
| NZ540657A (en) * | 2002-12-13 | 2006-09-29 | Alphavax Inc | High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine |
| CN1791678A (zh) * | 2003-03-20 | 2006-06-21 | 阿尔法瓦克斯公司 | 改进的甲病毒复制子和辅助构建体 |
| AU2004249802B2 (en) * | 2003-06-20 | 2007-06-28 | Microbix Biosystems Inc. | Improvements in virus production |
| DE602004021260D1 (de) * | 2003-07-11 | 2009-07-09 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| EP1751289B1 (en) | 2004-05-18 | 2009-01-14 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
| JP2008512443A (ja) * | 2004-09-09 | 2008-04-24 | カイロン ベーリング ゲーエムベーハー アンド カンパニー | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
| US7344839B2 (en) * | 2004-12-23 | 2008-03-18 | Aurx, Inc. | Virus preparations and methods |
| DK1960016T3 (en) | 2005-12-13 | 2017-01-09 | Exthera Medical Corp | Method for extracorporeal removal by a pathogenic MI-KROBE, an inflammatory cell or inflammatory protein from the blood. |
| US8003363B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| JP2010526546A (ja) | 2007-05-14 | 2010-08-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製 |
| US20080294361A1 (en) * | 2007-05-24 | 2008-11-27 | Popp Shane M | Intelligent execution system for the monitoring and execution of vaccine manufacturing |
| WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
| DK2947149T3 (en) | 2007-06-21 | 2018-06-06 | Alphavax Inc | ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION |
| WO2010019572A1 (en) * | 2008-08-11 | 2010-02-18 | Sanofi Pasteur Biologics Co. | Compositions and methods for the production of alpha-herpesviruses |
| EP2509604B1 (en) | 2009-12-01 | 2021-03-17 | ExThera Medical Corporation | Device for removing cytokines from blood with surface immobilized polysaccharides |
| WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
| CA2829774C (en) | 2011-03-14 | 2019-09-24 | National Research Council Of Canada | Method of viral production in cells |
| WO2013106398A1 (en) * | 2012-01-09 | 2013-07-18 | Sanofi Pasteur Biologics, Llc | Purification of herpes virus |
| WO2013177172A2 (en) | 2012-05-21 | 2013-11-28 | Sanofi Pasteur Limited | Herpesvirus compositions and related methods |
| EP2861273B1 (en) | 2012-06-13 | 2017-08-23 | ExThera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
| MX376935B (es) | 2013-06-24 | 2025-03-07 | Exthera Medical Corp | Sistema de filtración de sangre que contiene substrato recubierto con manosa. |
| CA2928866C (en) | 2013-11-08 | 2021-11-09 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
| AU2015250107A1 (en) | 2014-04-24 | 2016-11-17 | Exthera Medical Corporation | Method for removing bacteria from blood using high flow rate |
| CA2959975A1 (en) | 2014-09-22 | 2016-03-31 | Exthera Medical Corporation | Wearable hemoperfusion device |
| US10786615B2 (en) | 2016-03-02 | 2020-09-29 | Exthera Medical Corporation | Method for treating drug intoxication |
| US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
| WO2020231830A1 (en) | 2019-05-16 | 2020-11-19 | Exthera Medical Corporation | Method for modulating endothelial glycocalyx structure |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE209738C (pt) | ||||
| JPS5341202B2 (pt) | 1974-03-12 | 1978-11-01 | ||
| SE420977B (sv) * | 1976-03-18 | 1981-11-16 | Kabi Ab | Forfarande for rening och isolering av hepatitvirus for vaccinframstellning |
| GB2080682B (en) * | 1980-07-30 | 1984-03-28 | Ciba Geigy Ag | Antiherpetically active lipstick |
| US4515714A (en) * | 1983-03-09 | 1985-05-07 | Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute | Method for purification of hepatitis B virus surface antigen |
| JPS6153226A (ja) * | 1984-08-24 | 1986-03-17 | Chemo Sero Therapeut Res Inst | 単純ヘルペスサブユニツトワクチンの精製方法 |
| US5024836A (en) | 1987-05-04 | 1991-06-18 | Merck & Co., Inc. | Stable lyophilized live herpes virus vaccine |
| WO1992005263A1 (en) | 1990-09-25 | 1992-04-02 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
| JPH06234659A (ja) | 1992-05-05 | 1994-08-23 | Handai Biseibutsubiyou Kenkyukai | 安定化生ワクチン |
| US5360736A (en) | 1992-06-04 | 1994-11-01 | Merck & Co., Inc. | Process for attenuated varicella zoster virus vaccine production |
| WO1993024616A1 (en) | 1992-06-04 | 1993-12-09 | Merck & Co., Inc. | Process for attenuated varicella zoster virus vaccine production |
| EP0689603A1 (en) | 1993-03-19 | 1996-01-03 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| US5447859A (en) * | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
-
1998
- 1998-03-05 GB GBGB9804632.9A patent/GB9804632D0/en not_active Ceased
-
1999
- 1999-03-05 AT AT99937941T patent/ATE316571T1/de not_active IP Right Cessation
- 1999-03-05 DE DE69929612T patent/DE69929612T2/de not_active Expired - Lifetime
- 1999-03-05 ES ES99937941T patent/ES2257867T3/es not_active Expired - Lifetime
- 1999-03-05 CA CA002322615A patent/CA2322615A1/en not_active Abandoned
- 1999-03-05 EP EP99937941A patent/EP1062325B1/en not_active Expired - Lifetime
- 1999-03-05 DK DK99937941T patent/DK1062325T3/da active
- 1999-03-05 BR BR9908424-4A patent/BR9908424A/pt not_active Application Discontinuation
- 1999-03-05 WO PCT/GB1999/000669 patent/WO1999045104A2/en not_active Ceased
- 1999-03-05 AU AU32665/99A patent/AU3266599A/en not_active Abandoned
- 1999-03-05 PT PT99937941T patent/PT1062325E/pt unknown
- 1999-03-05 JP JP2000534636A patent/JP2002505101A/ja active Pending
- 1999-03-05 US US09/263,140 patent/US6267967B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999045104A3 (en) | 1999-11-04 |
| CA2322615A1 (en) | 1999-09-10 |
| EP1062325A2 (en) | 2000-12-27 |
| AU3266599A (en) | 1999-09-20 |
| US6267967B1 (en) | 2001-07-31 |
| JP2002505101A (ja) | 2002-02-19 |
| DE69929612D1 (de) | 2006-04-13 |
| DE69929612T2 (de) | 2006-11-02 |
| WO1999045104A2 (en) | 1999-09-10 |
| ATE316571T1 (de) | 2006-02-15 |
| PT1062325E (pt) | 2006-05-31 |
| ES2257867T3 (es) | 2006-08-01 |
| DK1062325T3 (da) | 2006-05-15 |
| GB9804632D0 (en) | 1998-04-29 |
| EP1062325B1 (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9908424A (pt) | Processo para purificar uma preparação de herpesvìrus | |
| FI973363A0 (fi) | Nukleiinihappoja sisältävä koostumus, sen valmistus ja käyttö | |
| AU4861890A (en) | Alkylated polyethylenimine derivatives, process for their preparation, their use as pharmaceuticals and pharmaceutical preparations | |
| ES2042058T3 (es) | Procedimiento para preparar apoliproteinas a partir de fracciones de plasma sanguineo o suero. | |
| CA2169834A1 (en) | Pharmaceutical formulations of nerve growth factor | |
| BR9915940A (pt) | Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53 | |
| NO20003716L (no) | Protein D for anvendelse in vitro, renset antistoff som binder proteinet, samt anvendelser derav | |
| FI930270A7 (fi) | Kefalosporiinit ja homologit, valmistusmenetelmät sekä farmaseuttiset koostumukset | |
| BR9711457A (pt) | Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas. | |
| FI931499A7 (fi) | Syklopeptidit, menetelmä niiden valmistamiseksi ja niiden käyttö lääke aineina | |
| ATE321859T1 (de) | B2microglobulin fusionsproteine und varianten mit hoher affinität | |
| CA2132328A1 (en) | Vaccine Containing Live Virus for Therapy of Viral Diseases and Malignancies | |
| FI72143C (fi) | Foerfarande foer framstaellning av maenniskointerferon. | |
| DE69023648D1 (de) | Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung. | |
| Bleszynski et al. | Some properties of the sulphatase B of ox brain | |
| BR0016212A (pt) | Proteìna especìfica do cromossoma sexual e sequência de ácido nucleico isolada e purificada, método para identificar moléculas especìficas de cromossomas sexuais associadas com membranas celulares de esperma animal, anticorpo contra um epìtopo de uma molécula especìfica de cromossomas sexuais, métodos de triagem para uma molécula especifica de cromossomas sexuais, e para separar esperma determinante de macho e fêmea de sêmen nativo kit para executar um método, contraceptivo, proteìna especìfica do cromossoma sexual isolada e purificada, e , molécula | |
| EP0373540A3 (en) | Method for purifying fibroblast growth factor protein | |
| GB2131294A (en) | Low molecular weight angiogenic factor | |
| EP0203382A2 (de) | Verfahren zur Herstellung und Reinigung von alpha-Interferon | |
| RU94042742A (ru) | Препарат генно-инженерного гамма-интерферона | |
| GR3006970T3 (pt) | ||
| NO20073809L (no) | Viruspreparater og fremgangsmater | |
| ATE130628T1 (de) | Antioxydantsystem auf basis einer basischen aminosäure und eines tocopherols. | |
| FI946136A7 (fi) | Substituoidut bentseenisulfonyylivirtsa-aineet ja -tiovirtsa-aineet, niiden valmistusmenetelmät ja näihin yhdisteisiin perustuvien farmaseuttisten valmisteiden käyttö | |
| Schenkein et al. | Dialyzable cofactor in nerve growth promoting protein from mouse salivary glands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |